Drug patent is lost.
The High Court ruling yesterday opens the way for cheaper copycat versions of Seretide - also known as Advair - to go on sale in Britain, potentially taking a sizeable chunk out of GSK's profits.
India's Cipla Ltd, US-based Ivax Corp and two other companies manufacturing generic versions of GSK's asthma treatment had challenged a key patent on the drug which expires in 2013.
A spokesman for GSK, which employs 2,200 people in Barnard Castle, County Durham and Ulverston in Cumbria, said the company would be appealing against the ruling.
Seretide/Advair was Glaxo's top-selling product in 2003.
It built global sales of pounds 2.2bn, with 6pc of the total being generated in Britain.
While analysts say the ruling will only affect a small part of Glaxo's market, they fear it could pave the way for further challenges which may affect other countries.
|Printer friendly Cite/link Email Feedback|
|Publication:||The Journal (Newcastle, England)|
|Date:||Mar 20, 2004|
|Previous Article:||Amec's second contract in days.|
|Next Article:||Profits leap at Nike.|